New drug BW-41012 enters first human safety tests
NCT ID NCT07584876
First seen Jun 24, 2026 · Last updated Jul 10, 2026 · Updated 3 times
Summary
This early-phase trial will test the safety and tolerability of a single injection of BW-41012 in 40 healthy adults aged 18 to 65. Participants will be randomly assigned to receive either the drug or a placebo, and researchers will monitor for side effects and measure how the drug behaves in the body. The study does not aim to treat any disease, but to gather essential safety data before moving to patient trials.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- BW-41012 (injection)
- What could go wrong
- This is a very early, small study in healthy people, not patients. It only checks safety and how the drug moves in the body, not whether it works for any disease. Many early-stage drugs fail to show benefit later.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HV are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Argo Investigative Site
RECRUITINGPerth, Western Australia, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.